VulnerabilityModified
CVE-2022-26235
A vulnerability was discovered in the Remisol Advance v2.0.12.1 and below for the Normand Message Server.
HIGH 7.8EPSS 0.19%
Does this matter?
High impact if exploited, but EPSS currently rates exploitation as unlikely (0.19%). Schedule it in the normal patch cycle and watch for a rise in EPSS or a public exploit.
Description
A vulnerability was discovered in the Remisol Advance v2.0.12.1 and below for the Normand Message Server. On installation, the permissions set by Remisol Advance allow non-privileged users to overwrite and/or manipulate executables and libraries that run as the elevated SYSTEM user on Windows.
- CVSS 3.1
- 7.8 HIGHCVSS:3.1/AV:L/AC:L/PR:L/UI:N/S:U/C:H/I:H/A:H
- EPSS
- 0.19% probability · 9th percentile
- CISA KEV
- Not listed
- Weakness
- CWE-276
- Affected
- beckmancoulter/remisol advance
- Source
- cve@mitre.org
References
- https://pastebin.com/amgw9pE7Third Party Advisory
- https://www.beckmancoulter.com/products/clinical-information-management-tools/remisol-advanceProduct, Vendor Advisory
- https://pastebin.com/amgw9pE7Third Party Advisory
- https://www.beckmancoulter.com/products/clinical-information-management-tools/remisol-advanceProduct, Vendor Advisory
Source: NVD record, EPSS from FIRST.org, KEV from CISA. Refreshed daily.